1
|
Vincze B, Gáspárdy A, Kézér FL, Pálffy M, Bangha Z, Szenci O, Kovács L. Fetal metacarpal/metatarsal bone thickness as possible predictor of dystocia in Holstein cows. J Dairy Sci 2018; 101:10283-10289. [PMID: 30197149 DOI: 10.3168/jds.2018-14658] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Accepted: 07/13/2018] [Indexed: 11/19/2022]
Abstract
Dystocia and perinatal calf mortality cause significant economic losses in the dairy cattle industry. Despite advanced ultrasound examination procedures, there is no reliable method to estimate the birth weight of calves in order to predict, prepartum, the risk of dystocia. The aim of this study was to predict calf birth weight and dystocia based on transrectal ultrasonographic (TRUS) examinations in late-term Holstein heifers and cows. Therefore, TRUS examination was performed on 128 animals that were between 265 and 282 d of gestation to measure the bone thickness of the fetal metacarpus (MC) or metatarsus (MT). Fetal TRUS measurements were successful in 104 cases. Excluding twin deliveries, 97 fetal MC/MT bone thicknesses were measured and the mean (±SD) MC/MT thickness was 2.54 ± 0.37 cm. A novel index, the metacarpal/metatarsal index [MCTI = maternal body weight (kg)/fetal MC or MT thickness (cm)], was also calculated to study its association with calving ease. The average MCTI was 257.3 kg/cm in the studied population. A lower MCTI was associated with the risk of dystocia with an odds ratio of 2.074 that was not significantly different from 1 (95% confidence interval: 0.002-11.104). Fetal presentation, fetal age, fetal sex, body condition score of the dam, age of dam, and intercoxal and interischiadic distances were not related to dystocia. A fair phenotypic correlation (0.226) was found between MC/MT thickness and calf birth weight. The genetic correlation between MC/MT thickness and calf birth weight was 0.235. Our results indicate that late-term measurement of the fetal MC/MT bone thickness by means of TRUS examination augmented with the MCTI may have clinical significance in the prediction of dystocia in Holstein cattle. Because the odds ratio for dystocia based on MCTI determination was not significant, the applied technique should be improved based on further studies on prepartum TRUS examinations combined with dam pelvic measurements.
Collapse
Affiliation(s)
- B Vincze
- MTA-SZIE Large Animal Clinical Research Group, Üllő-Dóra major H-2225, Hungary; Department of Animal Breeding, Nutrition and Laboratory Animal Science, University of Veterinary Medicine, István utca 2, Budapest H-1078, Hungary
| | - A Gáspárdy
- Department of Animal Breeding, Nutrition and Laboratory Animal Science, University of Veterinary Medicine, István utca 2, Budapest H-1078, Hungary
| | - F L Kézér
- MTA-SZIE Large Animal Clinical Research Group, Üllő-Dóra major H-2225, Hungary; Institute of Animal Husbandry, Faculty of Agricultural and Environmental Science, Szent István University, Páter Károly utca 1, Gödöllő H-2100, Hungary
| | - M Pálffy
- MTA-SZIE Large Animal Clinical Research Group, Üllő-Dóra major H-2225, Hungary
| | - Zs Bangha
- Institute of Animal Husbandry, Faculty of Agricultural and Environmental Science, Szent István University, Páter Károly utca 1, Gödöllő H-2100, Hungary
| | - O Szenci
- MTA-SZIE Large Animal Clinical Research Group, Üllő-Dóra major H-2225, Hungary
| | - L Kovács
- MTA-SZIE Large Animal Clinical Research Group, Üllő-Dóra major H-2225, Hungary; Institute of Animal Husbandry, Faculty of Agricultural and Environmental Science, Szent István University, Páter Károly utca 1, Gödöllő H-2100, Hungary.
| |
Collapse
|
2
|
Adamek M, Baska F, Vincze B, Steinhagen D. Carp edema virus from three genogroups is present in common carp in Hungary. J Fish Dis 2018; 41:463-468. [PMID: 29064105 DOI: 10.1111/jfd.12744] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Revised: 09/11/2017] [Accepted: 09/12/2017] [Indexed: 06/07/2023]
Abstract
Hungary is an important carp producer with intensive trading relationships with farms in other carp-producing areas in Europe. Carp in Europe were recently found infected with carp edema virus (CEV), a poxvirus which causes the koi sleepy disease (KSD) syndrome. Moribund carp were collected from 17 fish farms and angling ponds in different regions of Hungary. Histological analysis of gills from these carp revealed a proliferation of the interlamellar epithelium and an infiltration by eosinophilic cells. In 13 of 17 of these carp, CEV DNA was detected by qPCR and in seven fish more than 1 × 104 copies of virus-specific DNA sequences per 250 ng of DNA, which could be considered as clinically relevant and a cause of disease. A phylogenetic analysis of the sequences revealed that all three genogroups of CEV were present in Hungarian common carp with genogroup I being most abundant. These results support the hypothesis of a prolonged presence of CEV in European carp populations and suggest that previous outbreaks of KSD were not recorded or misdiagnosed. Hence, a testing of carp and koi for infection with CEV should be included into disease surveillance programmes to prevent further spreading of this disease.
Collapse
Affiliation(s)
- M Adamek
- Fish Disease Research Unit, Institute of Parasitology, University of Veterinary Medicine Hannover, Hannover, Germany
| | - F Baska
- Department of Pathology, University of Veterinary Medicine, Budapest, Hungary
| | - B Vincze
- Department of Animal Breeding, Nutrition and Laboratory Animal Science, University of Veterinary Medicine, Budapest, Hungary
| | - D Steinhagen
- Fish Disease Research Unit, Institute of Parasitology, University of Veterinary Medicine Hannover, Hannover, Germany
| |
Collapse
|
3
|
Pató J, Móra M, Mezö I, Seprödi J, Teplán I, Vincze B, Kálnay A, Pályi I. Synthesis of New Poly(N-Vinyl Pyrrolidone-Co-Maleic Acid) Peptide Hormone Conjugates with Anticancer Activity. J BIOACT COMPAT POL 2016. [DOI: 10.1177/088391159901400402] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Gonadotropin releasing hormone (GnRH) is a decapeptide regulating the gonadotropin release in organisms. Its analogues inhibit breast, endometrium and prostatic tumor cell proliferation in vitro. Some analogues were conjugated via the lysine side chain to poly( N-vinyl pyrrolidone- co-maleic acid) using biodegradable and non-biodegradable oligopeptide spacers. The conjugates were prepared by acylation of oligopeptide nitrophenyl esters with the polymeric precursor, poly( N-vinyl pyrrolidone- co-maleic anhydride), by reacting the GnRH analogues with the polymeric active ester. In vitro tests of these products exhibited increased effects on MCF-7 and MDA MB-231 breast, Ishikawa endometrium and PC3 prostatic human tumor cells compared with the parent decapeptides.
Collapse
Affiliation(s)
- János Pató
- Central Research Institute for Chemistry, POB 17 1525, Budapest, Hungary
| | - Melinda Móra
- Central Research Institute for Chemistry, POB 17 1525, Budapest, Hungary
| | - Imre Mezö
- Semmulweis University Medical School, Puskin u. 9 1080, Budapest, Hungary
| | - János Seprödi
- Semmulweis University Medical School, Puskin u. 9 1080, Budapest, Hungary
| | - István Teplán
- Semmulweis University Medical School, Puskin u. 9 1080, Budapest, Hungary
| | - Borbála Vincze
- National Institute of Oncology, Ráth Gy. u. 7-9 1122, Budapest, Hungary
| | - Adrienn Kálnay
- National Institute of Oncology, Ráth Gy. u. 7-9 1122, Budapest, Hungary
| | - István Pályi
- National Institute of Oncology, Ráth Gy. u. 7-9 1122, Budapest, Hungary
| |
Collapse
|
4
|
Kapuvári B, Hegedüs R, Schulcz Á, Manea M, Tóvári J, Gacs A, Vincze B, Mező G. Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice. Invest New Drugs 2016; 34:416-23. [PMID: 27146514 PMCID: PMC4919375 DOI: 10.1007/s10637-016-0354-7] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2016] [Accepted: 04/12/2016] [Indexed: 12/01/2022]
Abstract
Compared to classical chemotherapy, peptide-based drug targeting is a promising therapeutic approach for cancer, which can provide increased selectivity and decreased side effects to anticancer drugs. Among various homing devices, gonadotropin-releasing hormone-III (GnRH-III) peptide represents a suitable targeting moiety, in particular in the treatment of hormone independent tumors that highly express GnRH receptors (e.g. colon carcinoma). We have previously shown that GnRH-III[4Lys(Ac),8Lys(Dau = Aoa)] bioconjugate, in which daunorubicin was attached via oxime linkage to the 8Lys of a GnRH-III derivative, exerted significant in vivo antitumor effect on subcutaneously developed HT-29 colon tumor. In contrast, results of the study reported here indicated that this compound was not active on an orthotopically developed tumor. However, if Lys in position 4 was acylated with butyric acid instead of acetic acid, the resulting bioconjugate GnRH-III[4Lys(Bu),8Lys(Dau = Aoa)] had significant tumor growth inhibitory effect. Furthermore, it prevented tumor neovascularization, without detectable side effects. Nevertheless, the development of metastases could not be inhibited by the bioconjugate; therefore, its application in combination with a metastasis preventive agent might be necessary in order to achieve complete tumor remission. In spite of this result, the treatment with GnRH-III[4Lys(Bu),8Lys(Dau = Aoa)] bioconjugate proved to have significant benefits over the administration of free daunorubicin, which was used at the maximum tolerated dose.
Collapse
Affiliation(s)
| | - Rózsa Hegedüs
- MTA-ELTE, Research Group of Peptide Chemistry, Pázmány P. stny. 1/A, Budapest, 1117, Hungary
| | - Ákos Schulcz
- National Institute of Oncology, Budapest, 1122, Hungary
| | - Marilena Manea
- Department of Chemistry and Zukunftskolleg, University of Konstanz, 78457, Constance, Germany
| | - József Tóvári
- National Institute of Oncology, Budapest, 1122, Hungary
| | | | | | - Gábor Mező
- MTA-ELTE, Research Group of Peptide Chemistry, Pázmány P. stny. 1/A, Budapest, 1117, Hungary.
| |
Collapse
|
5
|
Kapuvári B, Schulcz Á, Hegedüs R, Szabó I, Manea M, Vincze B, Tóvári J, Gacs A, Tejeda M, Gaál D, Mezõ G. [Studying the tumor growth inhibitory effect of modified GnRH-III-anthracycline bioconjugates in subcutaneous vs. orthotopic models in vivo]. Magy Onkol 2015; 59:310-318. [PMID: 26665191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2015] [Accepted: 10/15/2015] [Indexed: 06/05/2023]
Abstract
Targeted tumor therapy is a perspective procedure to specifically destroy the cancer tissues with eliminating or at least decreasing the side effects of anticancer drugs. For this purpose the drug molecule is attached to a targeting moiety (e.g. peptide hormones) that recognizes tumor specific or overexpressed receptors on cancer cells. The in vitro cytostatic or cytotoxic assays do not give proper information whether the tumor growth inhibitory effect of the conjugate is better than the activity of the free drug. Only in vivo studies are adequate to answer this question. However, the selection of the appropriate tumor model is important to eliminate the false positive results. In our studies a gonadotropin-releasing hormone analog (GnRH-III) was applied as targeting moiety in drug conjugates. The in vivo antitumor activity of these conjugates was investigated on mice bearing subcutaneously or orthotopically szigdeveloped tumors. The subcutaneously implanted tumor model which is isolated from its surroundings may provide false results in tumor growth inhibition. In contrast, the orthotopically developed tumor is a better model representing appropriate anatomical and clinical status of cancer. Therefore, the orthotopical colon cancer developed in our laboratory is a suitable model for the study of the antitumor activity of the conjugates prepared for targeted tumor therapy.
Collapse
Affiliation(s)
- Bence Kapuvári
- Biokémiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Ákos Schulcz
- Kísérletes Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary
| | - Rózsa Hegedüs
- Peptidkémiai Kutatócsoport, ELTE-MTA, Budapest, Hungary
| | - Ildikó Szabó
- Peptidkémiai Kutatócsoport, ELTE-MTA, Budapest, Hungary
| | - Marilena Manea
- Zukunftskolleg, University of Konstanz, Department of Chemistry, Konstanz, Germany
| | - Borbála Vincze
- Biokémiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - József Tóvári
- Kísérletes Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary
| | - Alexandra Gacs
- Kísérletes Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary
| | - Miguel Tejeda
- Kísérletes Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary
| | - Dezsõ Gaál
- Kísérletes Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary
| | - Gábor Mezõ
- Peptidkémiai Kutatócsoport, ELTE-MTA, Budapest, Hungary
| |
Collapse
|
6
|
Vincze B, Kapuvári B, Udvarhelyi N, Horváth Z, Mátrai Z, Czeyda-Pommersheim F, Kőhalmy K, Kovács J, Boldizsár M, Láng I, Kásler M. Serum estrone concentration, estrone sulfate/estrone ratio and BMI are associated with human epidermal growth factor receptor 2 and progesterone receptor status in postmenopausal primary breast cancer patients suffering invasive ductal carcinoma. Springerplus 2015; 4:387. [PMID: 26240785 PMCID: PMC4520825 DOI: 10.1186/s40064-015-1171-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/20/2015] [Accepted: 07/20/2015] [Indexed: 12/30/2022]
Abstract
Background We investigated in postmenopausal women with primary breast cancer prior to surgical intervention whether, serum levels of different steroid hormones and hormonal precursors associated with tumor tissue estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Methods We enrolled 1,042 patients suffering invasive ductal carcinoma undergoing surgical resection in the National Institute of Oncology, Hungary between 2003 and 2011. Serum parameters were measured by RIA/IRMA assays; tumor tissue ER, PR and HER2 status was assessed histologically. Patients were classified according to tumor receptor status. Case–case analysis subjects were categorized into four subgroups based on serum hormone concentrations in ER, PR and HER2 receptor-negative cases, respectively. Results Serum estrone sulfate and dehydroepiandrosterone sulfate levels correlated with each other and also with serum estrone and estradiol levels. According to case–case study the odds ratios in the highest quartile were 1.517 (p = 0.0305, Ptrend = 0.0394) for androstenedione, 1.495 (p = 0.0317, Ptrend < 0.0105) for estrone and 0.654 (p = 0.0273, Ptrend < 0.0151) for estrone sulfate/estrone ratio in PR+ vs. PR− tumors. Regarding HER2 status (HER2+ vs. HER2−), the odds ratios for estrone, estrone sulfate and estrone sulfate/estrone ratio were 0.530 (p = 0.0234, Ptrend = 0.0595), 2.438 (p = 0.0042, Ptrend < 0.0066) and 3.118 (p = 0.0001, Ptrend < 0.0001) in the highest quartile, respectively. Of note significantly increased BMI associates with PR+ and ER +/PR+ status while significantly decreased BMI was observed in HER2+ cases. Conclusions Taken together, measurement of serum estrone and estrone sulfate concentrations prior to surgical intervention might support the individualization of regime in postmenopausal primary breast cancer patients.
Collapse
Affiliation(s)
- Borbála Vincze
- Department of Biochemistry, National Institute of Oncology, 1122 Budapest, Ráth György u. 7-9., Hungary
| | - Bence Kapuvári
- Department of Biochemistry, National Institute of Oncology, 1122 Budapest, Ráth György u. 7-9., Hungary
| | - Nóra Udvarhelyi
- Surgical and Molecular Tumor Pathology Centre, National Institute of Oncology, Budapest, Hungary
| | - Zsolt Horváth
- Clinic of Oncology, Centre of Clinics, University of Debrecen, 4032 Debrecen, Nagyerdei krt. 98., Hungary
| | - Zoltán Mátrai
- Department of General and Thoracic Surgery, National Institute of Oncology, Budapest, Hungary
| | | | - Krisztina Kőhalmy
- Department of Biochemistry, National Institute of Oncology, 1122 Budapest, Ráth György u. 7-9., Hungary
| | - Judit Kovács
- Department of Biochemistry, National Institute of Oncology, 1122 Budapest, Ráth György u. 7-9., Hungary
| | - Mariann Boldizsár
- Department of Biochemistry, National Institute of Oncology, 1122 Budapest, Ráth György u. 7-9., Hungary
| | - István Láng
- Medical Oncology and Clinical Pharmacology "B", National Institute of Oncology, Budapest, Hungary
| | | |
Collapse
|
7
|
Abstract
GnRH (gonadotropin-releasing hormone), a decapeptide produced by the hypothalamus, plays an important role in the reproduction by regulating the pituitary-gonadal axis. Continuous high doses of GnRH or its superactive agonists result in desensitization of the pituitary gonadotropes and a suppression of sex steroid production by the gonads (chemical castration). Based on these effects, the treatment with GnRH agonists has become a widely used hormonal therapy of the sex-steroid dependent tumors. It was also demonstrated that most tumor cells contain GnRH receptors, and the direct antiproliferative effect of GnRH analogs on cancer cells might be mediated by these receptors. Development of new GnRH derivatives is focused on the decrease of their hormonal potency resulting in higher selectivity of the antitumor activity. One of the most promising natural GnRH analogs, lamprey (l) lGnRH-III, was isolated from see lamprey. This variant of GnRH binds to GnRH receptors and inhibits proliferation of various cancer cells. However, its endocrine effect is insignificant in mammals. lGnRH-III dimers and conjugates were prepared and were shown to have increased antiproliferative effects on various cancer cells, while their hormonal activity was lower than that of the native hormone. lGnRH-III was applied as targeting moiety to deliver anticancer agents to tumor cells. Research data concerning lGnRH-III and its analogs represent a new outlook for research trends of the application of GnRH compounds in cancer chemotherapy. Studies on the effects of lGnRH-III derivatives including antiproliferative effects, cytotoxicity, hormonal actions, and enzymatic stability are reviewed in this article.
Collapse
Affiliation(s)
- Gábor Mezo
- Department of Anatomy, University of Pécs, Medical School, 7624 Pécs, Hungary
| | | | | | | | | |
Collapse
|
8
|
Szabo I, Bosze S, Kovacs M, Vincze B, Csuka O, Hudecz F, Mezo G. Antiproliferative effect of GNRH-III and GNRH-II peptide derivatives on MCF-7, T47-d and HT-29 cells. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)71441-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
9
|
Vincze B. [Report of the Treasurer, Society of Hungarian Oncologists, November 2005 to November 2007)]. Magy Onkol 2008; 52:99-101. [PMID: 18403305 DOI: 10.1556/monkol.52.2008.1.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
|
10
|
Remenár E, Számel I, Budai B, Vincze B, Gaudi I, Gundy S, Kásler M. Increase of hypophyseal hormone levels in male head and neck cancer patients. Pathol Oncol Res 2007; 13:341-4. [PMID: 18158570 DOI: 10.1007/bf02940314] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2007] [Accepted: 09/20/2007] [Indexed: 11/29/2022]
Abstract
Head and neck squamous cell carcinoma (HNSCC) develops in at least 80% of cases in men with a history of smoking and heavy alcohol consumption, still it is only diagnosed in a small proportion of alcoholics. Endocrine milieu is an important factor in carcinogenesis and prognosis of several cancer types. The aim of our study was to investigate sex steroid and hypophyseal hormone status of male HNSCC patients in comparison to healthy volunteers and to patients with alcoholic liver disease, to determine possible hormonal alterations characteristic of cancer. Liver function (GGT level), and serum levels of gonadotropic hormones (FSH, LH, prolactin), sex steroids (estradiol, progesterone, testosterone) and sex hormone-binding globulin (SHBG) were compared in 130 male HNSCC patients, 54 patients with alcoholic liver disease but no known cancer, and 56 healthy controls. We found abnormal values of liver function in both HNSCC patients and alcoholics compared to healthy controls, suggesting the presence of alcoholic liver disease in the former group as well. On the other hand, a significant elevation in the level of DHEA, FSH and LH was observed in cancer patients exclusively. As a conclusion, abnormal alterations in sex steroid hormone levels can frequently be found in HNSCC patients, which may be caused in part by the alcoholic liver damage accompanying the disease. The significant increase in FSH and LH serum levels, observed only in the cancer patients, indicates that these hormones may play a role in the development and/or progression of HNSCC.
Collapse
Affiliation(s)
- Eva Remenár
- Department of Head and Neck, Laser and Reconstructive Plastic Surgery, National Institute of Oncology, Budapest, H-1122, Hungary.
| | | | | | | | | | | | | |
Collapse
|
11
|
Remenar E, Vincze B, Szamel I, Ladanyi A, Timar J, Kasler M. 5548 POSTER Circulating hormone levels and prognosis in head and neck cancer. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71265-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
12
|
Mezo G, Czajlik A, Manea M, Jakab A, Farkas V, Majer Z, Vass E, Bodor A, Kapuvári B, Boldizsár M, Vincze B, Csuka O, Kovács M, Przybylski M, Perczel A, Hudecz F. Structure, enzymatic stability and antitumor activity of sea lamprey GnRH-III and its dimer derivatives. Peptides 2007; 28:806-20. [PMID: 17254668 DOI: 10.1016/j.peptides.2006.12.014] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/11/2006] [Revised: 12/19/2006] [Accepted: 12/20/2006] [Indexed: 11/24/2022]
Abstract
Direct antitumor activity of sea lamprey (Petromyzon marinus) gonadotropin-releasing hormone III (Glp-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH(2); lGnRH-III) was described on several tumor cells. To improve the selectivity of antitumor effects without increasing the hormone releasing activity and to enhance the enzymatic stability, lGnRH-III dimers were prepared via disulfide bond formation. Our results demonstrate that the lGnRH-III dimer derivatives exhibited higher antiproliferative effect and enzymatic stability in comparison with the native lGnRH-III, while lower LH-releasing potency was determined. In order to find a correlation between the biological and structural features of these compounds, the conformation of lGnRH-III and its dimer derivatives was determined by ECD, VCD, FT-IR and (1)H NMR.
Collapse
Affiliation(s)
- Gábor Mezo
- Research Group of Peptide Chemistry, Hungarian Academy of Sciences, Eötvös L. University, POB 32, 1518 Budapest 112, Hungary.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Kovács M, Vincze B, Horváth JE, Seprodi J. Structure-activity study on the LH- and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-III analogs. Peptides 2007; 28:821-9. [PMID: 17289216 DOI: 10.1016/j.peptides.2007.01.003] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/09/2006] [Revised: 12/29/2006] [Accepted: 01/05/2007] [Indexed: 11/25/2022]
Abstract
UNLABELLED GnRH-III was reported to have selective FSH-releasing activity in rats and significant anticancer potency on human breast cancer cells. To improve either of these effects, 14 analogs were synthesized and investigated for FSH/LH stimulation and breast cancer inhibition. Analogs with single amino acid changes in positions 5-7 or 10 showed small or no difference in the FSH- or LH-releasing activity compared with GnRH-III but their anticancer potency decreased significantly. Modification of the terminal amino acids, side chain cyclization at the 6-8 regions, or combined amino acid changes at positions 4, 6 and/or 8 resulted in the decrease of both effects. Gonadotropin-releasing activity of Arg(8)-GnRH-III was improved 3-11-fold. A copolymer conjugate of GnRH-III showed 2-3-fold anticancer activity while losing endocrine potency. CONCLUSION The activation of GnRH-receptors on pituitary and breast cancer cells requires a specific structure and/or conformation that makes possible to improve the anticancer selectivity of GnRH analogs.
Collapse
Affiliation(s)
- Magdolna Kovács
- University of Pécs, Medical School, Department of Anatomy, Szigeti Str. 12, Pécs 7624, Hungary.
| | | | | | | |
Collapse
|
14
|
Szavcsur P, Godény M, Bajzik G, Lengyel E, Repa I, Trón L, Boér A, Vincze B, Póti Z, Szabolcs I, Esik O. Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients. Eur J Surg Oncol 2005; 31:183-90. [PMID: 15698736 DOI: 10.1016/j.ejso.2004.06.011] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/21/2004] [Indexed: 11/20/2022] Open
Abstract
AIM To report the role of liver angiography in the staging of medullary thyroid cancer (MTC) patients. MATERIAL AND METHODS Sixty MTC patients with persistent or recurrent hypercalcitonemia (n=49), a characteristic general symptom (diarrhea, n=4) or a normal basal calcitonin level without general symptoms (n=7) were investigated by dynamic liver CT, MRI and angiography between 06/1998 and 06/2002. RESULTS Dual-phase CT and MRI investigations identified hepatic metastases with relatively low frequency (8/58 on MRI, and 7/60 on CT). Angiography indicated liver involvement in 54/60 cases. The hepatic metastases were typically multiple, hypervascular, small foci (only 13 foci measured >/=10 mm). With one exception significant disease progression was not observed over 5 years of follow-up. CONCLUSIONS Liver angiography is a powerful tool to reveal hepatic metastases in MTC patients. Frequent, inoperable liver metastases in hypercalcitoninemic MTC patients demonstrate that secondary lymph node dissection is an inefficient technique for restoration of a normal calcitonin level.
Collapse
Affiliation(s)
- P Szavcsur
- Department of Diagnostic Imaging, National Institute of Oncology, Budapest, Hungary
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Kremmer T, Szöllösi E, Boldizsár M, Vincze B, Ludányi K, Imre T, Schlosser G, Vékey K. Liquid chromatographic and mass spectrometric analysis of human serum acid alpha-1-glycoprotein. Biomed Chromatogr 2005; 18:323-9. [PMID: 15236441 DOI: 10.1002/bmc.324] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Human serum acid alpha-1-glycoprotein (AGP, orosomucoid) content of healthy individuals and cancer patients was measured, isolated and purified using a protocol of fast and biocompatible sample preparation, ion exchange and dye-ligand affinity chromatographic methods. In comparison to the healthy individuals significantly higher serum AGP levels were found in a wide spectrum of cancer patients, indicating its diagnostic value in the malignant disease. Oligosaccharide content of AGP samples was separated following PNGase F enzyme digestion and analysed by RP-HPLC and MALDI-TOF mass spectrometry. RP-HPLC and MALDI-TOF mass spectrometric analysis of sugar constituents of AGP specimen originated from selected cancer patients with high serum AGP levels indicated the appearance of anomal distribution of bi-, tri- and tetra-antennary oligosaccharide structures compared to the healthy controls.
Collapse
Affiliation(s)
- T Kremmer
- National Institute of Oncology, Department of Biochemistry, PO Box 21, H 1122 Budapest, Hungary.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Gyergyay F, Gödény M, Sármay G, Kralovanszky J, Papp E, Gergye M, Vincze B, Kéri G, Bodrogi I. Antitumor activity and pharmacology of TT-232 (a novel somatostatin structural derivative) in malignant melanoma patients. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. Gyergyay
- National Institute of Oncology, Budapest, Hungary; Institute of Immunology, ELTE University, Budapest, Hungary; Research Organization of the Academy of Sciences, Budapest, Hungary
| | - M. Gödény
- National Institute of Oncology, Budapest, Hungary; Institute of Immunology, ELTE University, Budapest, Hungary; Research Organization of the Academy of Sciences, Budapest, Hungary
| | - G. Sármay
- National Institute of Oncology, Budapest, Hungary; Institute of Immunology, ELTE University, Budapest, Hungary; Research Organization of the Academy of Sciences, Budapest, Hungary
| | - J. Kralovanszky
- National Institute of Oncology, Budapest, Hungary; Institute of Immunology, ELTE University, Budapest, Hungary; Research Organization of the Academy of Sciences, Budapest, Hungary
| | - E. Papp
- National Institute of Oncology, Budapest, Hungary; Institute of Immunology, ELTE University, Budapest, Hungary; Research Organization of the Academy of Sciences, Budapest, Hungary
| | - M. Gergye
- National Institute of Oncology, Budapest, Hungary; Institute of Immunology, ELTE University, Budapest, Hungary; Research Organization of the Academy of Sciences, Budapest, Hungary
| | - B. Vincze
- National Institute of Oncology, Budapest, Hungary; Institute of Immunology, ELTE University, Budapest, Hungary; Research Organization of the Academy of Sciences, Budapest, Hungary
| | - G. Kéri
- National Institute of Oncology, Budapest, Hungary; Institute of Immunology, ELTE University, Budapest, Hungary; Research Organization of the Academy of Sciences, Budapest, Hungary
| | - I. Bodrogi
- National Institute of Oncology, Budapest, Hungary; Institute of Immunology, ELTE University, Budapest, Hungary; Research Organization of the Academy of Sciences, Budapest, Hungary
| |
Collapse
|
17
|
Vincze B, Sinkovics I, Keresztes S, Gergye M, Boér A, Remenár E, Péter I, Szentirmay Z, Kremmer T, Kásler M. [Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation]. Magy Onkol 2004; 48:27-34. [PMID: 15105893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2004] [Accepted: 01/26/2004] [Indexed: 05/24/2023]
Abstract
Serum thyroglobulin (Tg) is a suitable marker for differentiated thyroid carcinoma following total thyroid ablation. Between 1998 and 2003, serum samples from 715 papillary and 179 follicular tumor patients treated with total/nearly total thyroidectomy and radioiodine ablation therapy were collected. According to the "Guidelines for Oncotherapy in Hungary", serum Tg, antithyroglobulin antibody (TgAb), TSH and FT4 levels were measured in periods of 3 months following the first treatment and of 6 months after 2 years. In the present work the prognostic value of Tg and TgAb data of cancer patients with hormone substitution therapy were evaluated individually and retrospectively. Serum Tg and TgAb concentrations were measured with a highly sensitive immunoradiometric (IRMA) method, and with a second generation, broad epitope specificity competitive radioimmunoassay, respectively. TSH levels determined by fourth generation LIAISON kit were in a range of 0.05-0.10 mIU/L. Accuracy of measuring of Tg <1 ng/ml made it possible to select the low cut-off level (Tg <2 ng/ml) following total thyroidectomy. In the predominant part of TSH-suppressed patients (746/774, 96%) the serum Tg concentration was below the cut-off level of 2 ng/ml. The sensitivity of Tg determination in 59 TSH-suppressed thyroid cancer patients with lung and bone metastases was as high as 86 to 100%. On the contrary, the number of false negative data was high in cases with lymph node metastases of papillary cancer, and sensitivity did not exceed 62%. Specificity and sensitivity of Tg in TgAb negative patients were 91 to 100%. Based on our results it could be concluded that measuring of Tg and TgAb, using a current IRMA method and a second generation RIA kit, proved to be effective tools for the postoperative monitoring of differentiated thyroid tumours. It has to be noted that determination of TgAb is highly recommended for the adequate interpretation of serum Tg levels. Persistently high and/or increasing serum TgAb concentration with low Tg result had a diagnostic value during the follow-up and can be connected with the recurrence or persistence of the differentiated thyroid cancer.
Collapse
Affiliation(s)
- Borbála Vincze
- Biokémiai Osztály, Országos Onkológiai Intézet, Budapest 1122, Hungary.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Sz�ll?si �, Kremmer T, Lud�nyi K, Imre T, Schlosser G, Boldizs�r M, Vincze B, V�key K. A Novel Method for the Separation and Purification of Human Serum Acid Alpha-1-Glycoprotein. Liquid Chromatographic and Mass Spectrometric Investigation of Tryptic Fragments. Chromatographia 2004. [DOI: 10.1365/s10337-004-0216-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
19
|
Abstract
AIM To report the role of different imaging methods in staging individuals with multiple endocrine neoplasia 2A (MEN2A) or familial medullary thyroid carcinoma (FMTC). MATERIAL AND METHODS Fourteen newly diagnosed gene carriers underwent cervical ultrasound scanning (US), cervical and mediastinal CT, MRI and whole-body meta-[131I]iodobenzylguanidine (MIBG) scintigraphy and [18F]fluorodeoxyglucose (FDG) PET scanning. RESULTS US identified seven true primary cancer. CT and MRI located only tumors > or =5 mm in diameter. MIBG scintigraphy and FDG PET could not identify MTC foci within the thyroid. Whole-body FDG PET identified two true-positive and one false-positive lymph node metastases. MIBG scintigraphy did not identify lymph node metastases. Total thyroidectomy was performed in 12 cases, and subtotal thyroidectomy in two subjects. CONCLUSIONS Whole-body FDG PET and cervical US help stage individuals carrying mutant genes verifying MEN2A or FMTC.
Collapse
Affiliation(s)
- A Boér
- Department of Head and Neck Surgery, National Institute of Oncology, Budapest, Hungary
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Kovacs M, Seprodi J, Koppan M, Horvath JE, Vincze B, Teplan I, Flerko B. Lamprey gonadotropin hormone-releasing hormone-III has no selective follicle-stimulating hormone-releasing effect in rats. J Neuroendocrinol 2002; 14:647-55. [PMID: 12153467 DOI: 10.1046/j.1365-2826.2002.00828.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Lamprey gonadotropin releasing-hormone (LGnRH)-III, a hypothalamic neurohormone recently isolated from sea lamprey, was reported to have a selective stimulatory effect on follicle-stimulating hormone (FSH) release in rats and suggested to be the mammalian FSH-releasing factor. In this study, we determined the relative luteinizing hormone (LH)- and FSH-releasing potency of LGnRH-III compared to mammalian gonadotropin-releasing hormone (LHRH) in normal female rats, ovariectomized (OVX) and oestrogen/progesterone substituted rats and the superfused rat-pituitary cell system. The specificity of LGnRH-III for the mammalian LHRH receptor was investigated by blocking the receptor with an LHRH antagonist, MI-1544. In vitro, LGnRH-III dose-dependently stimulated both LH and FSH secretion from rat pituitary cells at 10(-7) to 10(-5) M concentrations, while LHRH stimulated gonadotropin secretion at a 1000-fold lower doses (10(-10) to 10(-8) M). The difference between its LH- and FSH-releasing potency was similar to that of LHRH. LGnRH-III bound to high affinity binding sites on rat pituitary cells with a Kd of 6.7 nM, B(max)=113 +/- 27 fmol/mg protein. In vivo, LGnRH-III also stimulated both LH and FSH secretion in a dose-dependent manner and, similar to LHRH, induced a greater rise in the serum LH than the FSH level. In normal cycling rats, it showed 180-650-fold weaker potency than LHRH in stimulating LH secretion and 70-80-fold weaker effect in stimulating FSH secretion. In OVX rats, LGnRH-III demonstrated a similarly weak effect on both gonadotropins. It was found to be 40-210-fold less potent than LHRH regarding LH release and 50-160-fold weaker regarding FSH release. LHRH-receptor antagonist MI-1544 prevented both the LH- and the FSH-releasing effect of LGnRH-III both in vitro and in vivo. These results do not support the hypothesis that LGnRH-III might be the mammalian FSH-releasing factor but demonstrate that it is a weak agonist for the pituitary LHRH receptor and stimulates both gonadotropins in a dose-dependent fashion.
Collapse
Affiliation(s)
- M Kovacs
- University of Pecs, Medical School, Department of Human Anatomy, Pecs, Hungary.
| | | | | | | | | | | | | |
Collapse
|
21
|
Kálnay A, Pályi I, Vincze B, Mihalik R, Mezõ I, Pató J, Seprõdi J, Lovas S, Murphy RF. Influence on antiproliferative activity of structural modification and conjugation of gonadotropin-releasing hormone (GnRH) analogues. Cell Prolif 2001; 33:275-85. [PMID: 11063130 PMCID: PMC6496190 DOI: 10.1046/j.1365-2184.2000.00180.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The effect of various GnRH analogues, and their conjugates on proliferation, clonogenicity and cell cycle phase distribution of MCF-7 and Ishikawa human cancer cell lines was studied. GnRH-III, a sea lamprey GnRH analogue reduced cell proliferation by 35% and clonogenicity by 55%. Structural modifications either decreased, or did not alter biological activity. Conjugation of GnRH analogues including MI-1544, MI-1892, and GnRH-III with poly(N-vinylpyrrolidone-co-maleic acid) (P) through a tetrapeptide spacer GFLG(X) substantially increased the inhibitory effect of the GnRH analogues. The conjugate P-X-GnRH-III induced significant accumulation of cells in the G2/M phase; from 8% to 15.6% at 24 h and 9.8% to 15% at 48 h. It was concluded that conjugation of various GnRH analogues substantially enhanced their antiproliferative activity, strongly reduced cell clonogenicity and retarded cell progression through the cell division cycle at the G2/M phase.
Collapse
Affiliation(s)
- A Kálnay
- National Institute of Oncology, Budapest, Hungary
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Vincze B, Pato J, Kremmer T, Boldizsar M, Csuka O, Gaal D, Toth G, Seprodi J, Lovas S, Murphy R. Enzyme inhibitor derivative of targeted nonbiodegradable GnRH analogue conjugate with high anticancer selectivity. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)80775-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
23
|
|
24
|
Pályi I, Vincze B, Lovas S, Mezö I, Pató J, Kálnay A, Turi G, Gaál D, Mihalik R, Péter I, Teplán I, Murphy RF. Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. Proc Natl Acad Sci U S A 1999; 96:2361-6. [PMID: 10051647 PMCID: PMC26789 DOI: 10.1073/pnas.96.5.2361] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Conjugation of gonadotropin-releasing hormone (GnRH) analogues GnRH-III, MI-1544, and MI-1892 through lysyl side chains and a tetrapeptide spacer, Gly-Phe-Leu-Gly (X) to a copolymer, poly(N-vinylpyrrolidone-co-maleic acid) (P) caused increased antiproliferative activity toward MCF-7 and MDA-MB-231 breast, PC3 and LNCaP prostate, and Ishikawa endometrial cancer cell lines in culture and against tumor development by xenografts of the breast cancer cells in immunodeficient mice. MCF-7 cells treated with P-X-1544 and P-X-1892 displayed characteristic signs of apoptosis, including vacuoles in the cytoplasm, rounding up, apoptotic bodies, bleb formation, and DNA fragmentation. Conjugates, but not free peptides, inhibited cdc25 phosphatase and caused accumulation of Ishikawa and PC3 cells in the G2/M phase of the cell cycle after 24 h at lower doses and in the G1 and G2 phases after 48 h. Since P-X-peptides appear to be internalized, the increased cytotoxicity of the conjugates is attributed to protection of peptides from proteolysis, enhanced interaction of the peptides with the GnRH receptors, and/or internalization of P-X-peptide receptor complexes so that P can exert toxic effects inside, possibly by inhibiting enzymes involved in the cell cycle. The additional specificity of P-X-peptides compared with free peptides for direct antiproliferative effects on the cancer cells but not for interactions in the pituitary indicates the therapeutic potential of the conjugates.
Collapse
Affiliation(s)
- I Pályi
- National Institute of Oncology, Budapest, H-1525, P.O. Box 21, Hungary.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Lovas S, Pályi I, Vincze B, Horváth J, Kovács M, Mezö I, Tóth G, Teplán I, Murphy RF. Direct anticancer activity of gonadotropin-releasing hormone-III. J Pept Res 1998; 52:384-9. [PMID: 9894843 DOI: 10.1111/j.1399-3011.1998.tb00662.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
In previous studies GnRH-III, a variant of the hypothalamic neurohormone GnRH, was isolated from the brain of the sea lamprey and structurally characterized. GnRH-III is a hypothalamic neurohormone in both female and male sea lampreys. In the present work biological activities of GnRH-III in mammalian systems were examined. In superfused rat pituitary cells, GnRH-III at 1 nM to 100 nM neither induced LH-secretion nor inhibited the LH-secretion elicited by native GnRH and elicited LH release only at 1 microM. At high dose (500 microg/day) in vivo, GnRH-III behaved as a GnRH agonist, though, it was 1000-fold less active than ovurelin. The in vitro and in vivo results were in good agreement in showing that GnRH-III is only a weak agonist of the endocrine activity of GnRH. GnRH-III specifically bound to receptors on cancer cells and recognized not only the high-, but also the low-affinity binding sites. GnRH-III significantly suppressed growth of human cancer cells which have GnRH receptors. The inhibitory effect of GnRH-III on growth of cancer cells was specific and direct since the peptide did not have endocrine activity in the concentration range found to be effective in anticancer assays. GnRH-III inhibited equally the growth of ER-positive and -negative breast and TeR-positive and negative prostate cells.
Collapse
Affiliation(s)
- S Lovas
- Department of Biomedical Sciences, Creighton University, Omaha, Nebraska 68178, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Mezö I, Lovas S, Pályi I, Vincze B, Kálnay A, Turi G, Vadász Z, Seprödi J, Idei M, Gulyás E, Ötvös F, Mák M, Horváth JE, Teplán I, Murphy RF. Synthesis of Gonadotropin-Releasing Hormone III Analogs. Structure−Antitumor Activity Relationships. J Med Chem 1998. [DOI: 10.1021/jm9801152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
Mezô I, Seprôdi J, Vincze B, Pályi I, Kéri G, Vadász Z, Tóth G, Kovács M, Koppán M, Horváth JE, Kálnay A, Teplán I. Synthesis of GnRH analogs having direct antitumor and low LH-releasing activity. Biomed Pept Proteins Nucleic Acids 1997; 2:33-40. [PMID: 9346824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
New chicken I GnRH agonists and antagonists have been synthesized and tested for their biological activities. The common feature of these analogs was that the molecules had a beta-L-aspartyl residue inserted in position 6. The agonist bound to the pituitary still had low endocrinological activity. On the other hand, it exhibited direct antitumor effect in in vitro assays. The endocrinological activity of the antagonist was low; however, it showed potent, direct antitumor activity. These observations might lead to the development of new GnRH analogs with selective antitumor effect.
Collapse
Affiliation(s)
- I Mezô
- Semmelweis University of Medicine, 1st Department of Biochemistry, Budapest, Hungary
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Mezö I, Lovas S, Pályi I, Vincze B, Kálnay A, Turi G, Vadász Z, Seprödi J, Idei M, Tóth G, Gulyás E, Otvös F, Mák M, Horváth JE, Teplán I, Murphy RF. Synthesis of gonadotropin-releasing hormone III analogs. Structure-antitumor activity relationships. J Med Chem 1997; 40:3353-8. [PMID: 9341910 DOI: 10.1021/jm9700981] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Following the observation that the activity of gonadotropin-releasing hormone III (GnRH-III) in the suppression of growth of MDA-MB-231 and MCF-7 breast cancer cells surpasses that of GnRH and other analogs thereof, analogs of GnRH-III were synthesized to investigate the structural basis for the improved antitumor activity. Compounds synthesized include analogs with changes in the central sequence in which GnRH-III differs from GnRH and in the C- and N-terminal regions. The results indicate that a salt bridge between Asp6 and Lys8 stabilizes the active conformation of GnRH-III and show the importance of the Trp7. Replacement of the C-terminal Gly-NH2 with D-Ala-NH2 was not well tolerated, but replacement with ethylamide was. Replacement of pGlu1 with Ac-D-Trp appears to have a significantly deleterious effect on a unique conformation of GnRH-III which is responsible for its binding to the receptors on cancer cell lines and the resultant antitumor activity.
Collapse
Affiliation(s)
- I Mezö
- Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University of Medicine, Budapest, Hungary
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Mezö G, Mezö I, Pimm MV, Kajtár J, Seprödi J, Teplán I, Kovács M, Vincze B, Pályi I, Idei M, Szekerke M, Hudecz F. Synthesis, conformation, biodistribution, and hormone-related in vitro antitumor activity of a gonadotropin-releasing hormone antagonist-branched polypeptide conjugate. Bioconjug Chem 1996; 7:642-50. [PMID: 8950483 DOI: 10.1021/bc9600574] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Since permanently high levels of GnRH analogues are necessary to exert direct and/or indirect antitumor effect on mammary tumors, much emphasis was put on the development of retarded-release devices (e.g. microcapsules) for GnRH derivatives. Alternatively, these compounds can be covalently coupled to high-molecular mass carrier molecules for the design of bioconjugates acting as (a) prodrugs producing prolonged release or (b) macromolecular therapeutics. In order to evaluate the feasibility of this approach, a prototype construct has been prepared with a potent GnRH antagonist Ac(D-Trp1,3, D-Cpa2, D-Lys6, D-Ala10)-GnRH (MI-1544). As a carrier, a representative of a new generation of synthetic, biodegradable branched poly[Lys(Xi-DL-Alam)] (XAK) type polypeptides with poly(L-lysine) backbone has been used in which X is an acetylated derivative of glutamic acid (AcEAK). This polyanionic polypeptide with free gamma-carboxyl groups was conjugated to MI-1544, which has only a single amino group at position 6. In this paper, we describe (i) the synthesis and structure (primary structure, conformation) properties of the MI-1544-AcEAK conjugate with a 33% degree of substitution, (ii) the effect of the covalent attachment of MI-1544 to AcEAK on its blood clearance and tissue distribution, and (iii) the hormone-related indirect (ovulation inhibitory) or direct (antiproliferative) antitumor activity of the conjugate studied by in vitro assays. Data obtained with 111In- and 125I-labeled conjugates have demonstrated that in fact the body/blood survival of MI-1544 was prolonged by 1.5-3 times. The direct in vitro antitumor effect of MI-1544 was maintained or even enhanced in the MI-1544-AcEAK conjugate. Furthermore, we have shown that this conjugate was able to antagonize the effect of GnRH in vitro or to act as free MI-1544 both in short- and long-term inhibition of ovulation even after single subcutaneous injection. These data suggest that it is feasible to use a biodegradable polymeric polypeptide for development of a macromolecular therapeutic with GnRH antagonists.
Collapse
Affiliation(s)
- G Mezö
- Research Group of Peptide Chemistry, Hungarian Academy of Sciences, Budapest, Hungary
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Vincze B, Pályi I, Daubner D, Kálnay A, Mezö G, Hudecz F, Szekerke M, Teplán I, Mezö I. Antitumour effect of a gonadotropin-releasing-hormone antagonist (MI-1544) and its conjugate on human breast cancer cells and their xenografts. J Cancer Res Clin Oncol 1994; 120:578-84. [PMID: 7929528 DOI: 10.1007/bf01212811] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Our gonadotropin-releasing hormone (GnRH) antagonist analogue MI-1544 ([Ac-D-Trp1,3,D-Cpa2,D-Lys6,D-Ala10]GnRH) was developed as a potential contraceptive material, because it decreased the luteinizing hormone level without unfavourable side-effects. The antagonist was covalently bound to poly[Lys-(Ac-Glu0.96-DL-Ala3.1)] (AcEAK)-a branched polypeptide having a polylysine backbone--resulting in a MI-1544-AcEAK conjugate. According to our in vitro experiments the MI-1544 induced a 33%-35% decrease in cell numbers of MCF-7 and MDA-MB-231 human breast cancer cell lines at a dose of 30 microM. The biodegradable polymeric carrier, AcEAK, alone inhibited cell proliferation by only 13%-15%, while the MI-1544-AcEAK conjugate, applied at the same dose, was capable of producing 45%-50% inhibition of cell proliferation. Our in vivo experiments using immunosuppressed mice showed that MI-1544, applied twice daily s.c., inhibited the growth of oestrogensensitive and -insensitive xenografts by 65% and 30% respectively. This effect was potentiated (70%) in both types of xenografts by the presence of the polymeric carrier in the conjugate; however, the carrier by itself did not cause tumour growth inhibition. The polymeric polypeptide carrier is supposed to increase the stability of the GnRH antagonist and to prevent the rapid excretion of the covalently bound peptide molecule. The antagonist and its conjugate may have various direct and indirect effects on breast cancer cells and, as a consequence, the new GnRH antagonist conjugates are suitable for treating an extended range of breast cancers.
Collapse
Affiliation(s)
- B Vincze
- National Institute of Oncology, Budapest, Hungary
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Svastics E, Számel I, Ringwald G, Vincze B, Besznyák I, Tóth J. [Clinical significance of steroid receptors in breast cancer]. Orv Hetil 1994; 135:513-7. [PMID: 8146006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The steroid receptor determination (first of all estrogen receptor--ER--) of the breast cancer tissue has become an important factor for prognostication and treatment. Authors from the Surgical Department of the National Institute of Oncology provide a biostatistical survey of their 727 breast cancer patients. Following factors proved to have significant impact on the prognosis: positivity of ER, the quantitative value of ER, ER vs. lymph node status, ER vs. DFI, ER and the site of metastases and the hormone therapy. The progesterone receptor (PR) provides indication in case only for DFI for metastases. However, in this very respect it has a more significant value than that of ER. Multidimensional analysis has shown that the most important prognostic factors are the lymph node status, patient's age, size of the tumour and the ER value.
Collapse
|
32
|
Abstract
In a combined phase I-II study, the hormonal effects of toremifene (TOR) were investigated in 30 patients. Half of the patients received continuous therapy of TOR 60 mg and half 300 mg of TOR orally daily. Serum concentrations of oestradiol (E2), progesterone (PROG), testosterone (TE), follicle stimulating hormone (FSH), luteinising hormone (LH), prolactin (PRL), human growth hormone (hGH) and sex hormone binding globulin (SHBG) were monitored prior to the treatment and at the second, sixth, eighth and twelfth weeks. The influence of TOR upon the hypothalamo-hypophyseal axis was investigated by the TRH (thyroid-stimulating hormone releasing hormone) functional test using 400 micrograms intravenous injection of TRH for stimulation of PRL secretion. The concentration of E2 decreased during the TOR therapy with 60 mg and 300 mg causing 82 and 71% decreases, respectively (non-significant). PRL was significantly (P < 0.001) suppressed. Both these effects reflect the anti-oestrogenic action of TOR. SHBG increased significantly at both doses of TOR, probably due to a direct oestrogen-like effect of TOR in the liver. TE decreased as a consequence of the elevated SHBG. The TRH-induced PRL release was suppressed by both doses of TOR. There were 17 and 27% reductions at 12 weeks in the 60 and 300 mg groups, respectively. Other hormones measured were not significantly affected by TOR. The hormonal effects of 60 and 300 mg doses of TOR did not differ significantly. Anti-oestrogenic (i.e. decrease of E2), and partially oestrogenic (i.e. increase of SHBG) properties as well as the antiprolactinic effects of TOR may have an overall beneficial effect in the clinical management of breast cancer patients.
Collapse
Affiliation(s)
- I Számel
- National Institute of Oncology, Budapest, Hungary
| | | | | | | | | | | |
Collapse
|
33
|
Pályi I, Péter I, Daubner D, Vincze B, Lõrincz I. Establishment, characterization and drug sensitivity of a new anaplastic thyroid carcinoma cell line (BHT-101). Virchows Arch B Cell Pathol Incl Mol Pathol 1993; 63:263-9. [PMID: 8099464 DOI: 10.1007/bf02899271] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
A thyroid carcinoma cell line, BHT-101, has been established in vitro from a metastatic lymph node deposit in a female patient with a non-hormone producing anaplastic, partly thyroglobulin- and thyroxine (T4)-positive papillary thyroid cancer. The cell population is heterogeneous, containing epithelial-like and fibroblast-like cells, and has a doubling time of 24 h. The cell line is polyploid with hypertetraploid predominance and the karyotype showed trisomies, tetrasomies, pentasomies as well as many marker chromosomes. The majority of the cells are negative or weakly positive for thyroglobulin and thyroxine and estrogen and progesterone receptors are present in the cells. BHT-101 cells produce tumours when injected into immunosuppressed CBA/Ca mice. The cells are sensitive to adriamycin, methotrexate and tamoxifen but not to methimazole (Favistan). The epithelial-like clone 1 and the fibroblast-like clone 3, isolated from the parental line, differed in drug sensitivity. This new cell line is suitable for studying the biology of thyroid carcinoma and for parallel in vivo and in vitro studies of drug activity against thyroid cancer.
Collapse
Affiliation(s)
- I Pályi
- Department of Cell Biology, National Institute of Oncology, Budapest, Hungary
| | | | | | | | | |
Collapse
|
34
|
Kremmer T, Pälyi I, Daubner D, Boldizsár M, Vincze B, Paulik E, Sugár J, Pokorny E, Túry E. Comparative studies on the polyamine metabolism and DFMO treatment of MCF-7 and MDA-MB-231 breast cancer cell lines and xenografts. Anticancer Res 1991; 11:1807-13. [PMID: 1768053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
In order to characterize the estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 human breast cancer cells and xenografts, their growth kinetic parameters and some biochemical characteristics concerning the receptor status and polyamine metabolism were determined and compared. The doubling times calculated from the growth curves showed higher proliferation rate of MDA-MB-231 cells, both in culture (21 hours) and in xenograft (9.7 days), in comparison to the MCF-7 cells which had values of 32 hours and 11.6 days, respectively. Growth-dependent changes observed in the intracellular putrescine, spermidine and spermine concentrations indicated a higher activity of polyamine metabolism in the MDA-MB-231 cells and xenograft as well. However, biosynthetic key-enzyme ornithine decarboxylase activity (ODC, EC 4.1.1.17) showed neither characteristic differences between the two types of breast cancer, nor consistent relationship with their proliferation rate. Metabolic alterations of the MCF-7 and MDA-MB-231 cell lines grown in vitro were also reflected in the polyamine composition of their culture medium. Independently of their receptor status, both types of breast cancer were responsive to difluoromethylornithine (DFMO) treatment. DFMO inhibited the ODC activity totally and depleted the cellular polyamine levels. MCF-7 cells in culture were more sensitive to the antitumoral effect of DFMO than the MDA-MB-231 line, while the rate of growth inhibition did not differ significantly in the xenografts. The present results provided further evidence on the different polyamine metabolism of ER-positive MCF-7 and ER-negative MDA-MB-231 human breast cancer cells in vitro and in vivo, suggesting a correlation of hormonal modulation with polyamines as a determinant group of biological response modifiers.
Collapse
Affiliation(s)
- T Kremmer
- National Institute of Oncology, Budapest, Hungary
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Számel I, Hindy I, Vincze B, Ady N, Eckhardt S. [The anti-estrogenic effect of 4-chloro-1,2-diphenyl-1-(4-[2-(N,N-dimethylamino)ethoxy]phenyl)1-butene (Toremifene) on the endocrine regulation in breast cancer patients]. Orv Hetil 1991; 132:683-6. [PMID: 1826556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
In a combined phase I-II study the hormonal effects of Toremifene were investigated in 15-15 patients at two dose levels: 60 mg and 300 mg per os, daily. Serum estradiol, progesterone, testosterone, follicle-stimulating hormone, luteinizing hormone, prolactin, human growth hormone were monitored by radioimmunoassay and sexual hormone binding globulin by immunoradiometric assay prior to treatment and at the 2nd, 8th and 12th weeks. The influence of Toremifene upon the hypothalamo-hypophyseal axis was also controlled by a tirotropin releasing hormone functional test using 400 micrograms tirotropin releasing hormone injection iv. Estradiol, progesterone, follicle-stimulating hormone, luteinizing hormone and prolactin decreased proving the antiestrogenic activity of the drug. Sexual hormone binding globulin significantly (p less than 0.002) increased by week 12 at both doses, probably due to a direct effect of Toremifene upon the liver. The increase in sexual hormone binding globulin suggests the partial estrogenic effect of the drug. The tirotropin releasing hormone induced prolactin release was also suppressed. On the basis of hormonal changes and the clinical response of patients 60 mg of Toremifene proved to be as effective as 300 mg.
Collapse
Affiliation(s)
- I Számel
- Országos Onkológiai Intézet, Budapest
| | | | | | | | | |
Collapse
|
36
|
Vincze B, Pályi I, Daubner D, Kremmer T, Számel I, Bodrogi I, Sugár J, Seprödi J, Mezö I, Teplán I. Influence of luteinizing hormone-releasing hormone agonists on human mammary carcinoma cell lines and their xenografts. J Steroid Biochem Mol Biol 1991; 38:119-26. [PMID: 2004034 DOI: 10.1016/0960-0760(91)90116-m] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The specific binding of luteinizing hormone-releasing hormone (LH-RH) agonist in estradiol-dependent MCF-7 and estradiol-independent MDA-MB-231 human breast cancer cells has been studied using [3H]Ovurelin [(D-3H-Phe6),des-Gly10-LH-RH- ethylamide]. The results of Scatchard analyses suggest the presence of a single class of receptor sites, both in cell suspensions and membrane fractions. Evaluation of these peptide receptors appears to reflect additional characteristics of biological behaviour of these human breast cancer cells. The synthetic LH-RH agonist Ovurelin [(D-Phe6),des-Gly10-LH-RH-ethylamide] can directly interfere (25-30%) with the proliferation of MDA-MB-231 human breast cancer cells in culture. The inhibitory effect of Ovurelin in vitro was negligible in the MCF-7 cell line. In the in vivo experiments the treated immunosuppressed mice bearing either MCF-7 or MDA-MB-231 xenografts responded to the high-dose LH-RH analogue Zoladex depot and Decapeptyl depot therapy. Since the MDA-MB-231 tumour was found to be ER-negative it seems possible that the regression of this xenograft results from the direct antitumor action of the LH-RH agonist.
Collapse
Affiliation(s)
- B Vincze
- National Institute of Oncology, Budapest, Hungary
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Számel I, Vincze B, Hindy I, Kerpel-Fronius S, Eckhardt S, Mäenpää J, Grönroos M, Kangas L, Sundquist H, Hajba A. Hormonal effects of toremifene in breast cancer patients. J Steroid Biochem 1990; 36:243-7. [PMID: 2142246 DOI: 10.1016/0022-4731(90)90018-n] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The effect of toremifene treatment on the serum levels of sex steroids (estradiol, progesterone, testosterone), FSH, LH, prolactin, TSH, T3, T4 and SHBG was investigated. Basal prolactin level and the "prolactin reserve capacity" of the hypophysis was also studied by the TRH functional test. Steroid hormone receptors were detected in the patients where a tumor biopsy could be obtained. In a randomized trial patients were treated by 60 and 300 mg of toremifene per os, daily. Hormone levels were assayed prior to treatment and at the 2nd, 6th, 8th and 12th week of tormifene therapy. The hormonal effects of toremifene were the most marked at the 2nd and at the 8th week. Estradiol decreased continuously, SHBG increased slightly and the high initial value of basal prolactin level decreased. The TRH-induced prolactin release was suppressed by tormifene after an 8-week period. No clinical response-related tendency was found.
Collapse
Affiliation(s)
- I Számel
- National Institute of Oncology, Budapest, Hungary
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Szántó J, Vincze B, Sinkovits I, Karika Z, Daubner K, Péter I, Kazatsay I, Eckhardt S. [Follow up of thyroglobulin levels in patients with surgically treated, highly differentiated thyroid cancer]. Orv Hetil 1989; 130:1695-9. [PMID: 2780041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The highly differentiated thyroid tumours account for 0.80 percent of all human malignancies. The papillary and follicular tumour tissues of this tumour type are relatively benign, hormone dependent and beside their treatment specificity they secrete the tumour specific thyreoglobulin. Thus it becomes possible to follow the development of metastases, the effectiveness of therapy applied as well as the history of the disease. The authors studied the change of thyreoglobulin level in 153 patients with highly differentiated thyroid cancer. In 29 of 32 metastatic patients pathologically elevated (70 to 100 ng/ml) thyreoglobulin level was observed. This proves the 91 percent specificity of the method in verified metastatic tumours. Compared to the total body scintigraphy 3 false negative cases were found. The authors establish that, irrespective of the site of metastasis, the thyreoglobulin level is higher in the follicular than in the papillary subtype. It is concluded that the measurement of the serum thyreoglobulin level is a suitable marker of the highly differentiated thyroid cancer since it represents the local recurrence of distant metastases with a significant increase while the therapy-resultant tumour diminution with a marked decrease, respectively.
Collapse
|
39
|
Szántó J, Vincze B, Kazatsay I. [Trends in the hormonal therapy of thyroid cancer]. Orv Hetil 1989; 130:1215-8. [PMID: 2499862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The highly differentiated thyroid cancers account for 0.70% of malignancies. Their management is primarily hormonal, in addition to the percutaneous irradiation and application of iodine isotope. This method is not aimed at the inhibition of the potential artificial hypothyreosis but mainly at the prevention of the tumour development or tumorous dissemination. The authors, in case of their 28 patients with the above diagnosis, tried to clarify if the TRH-tolerance TSH-level determination promotes the optimal patient management, the ideal hormone substitution lasting for several years. Their results suggest that the drugs containing L-thyroxin prove to be most effective in the clinical practice. Their optimal dose is 2.8-3.0 micrograms/kg. The study of the TRH-sensitized TSH-level does not primarily facilitate the ideal hormone substitution but may decrease the "unnecessary" amount of thyroid hormone-containing drugs. In view of the fact that the hormonal treatment may last even several decades for a patient, the authors considering economic points as well, do not reject the TRH-tolerance TSH-study. In their opinion the more favourable solution may be provided by the wide-scale application of the IRMA-TSH.
Collapse
|
40
|
Szántó J, Vincze B, Sinkovics I, Karika Z, Daubner K, Péter I, Kazatsay I, Eckhardt S. Postoperative thyroglobulin level determination to follow up patients with highly differentiated thyroid cancer. Oncology 1989; 46:99-104. [PMID: 2710483 DOI: 10.1159/000226694] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The highly differentiated thyroid tumours account for 0.80% of all human malignancies. The papillary and follicular tumour tissues of this tumour type are relatively benign, hormone-dependent and beside their treatment specificity they secrete the tumour-specific thyroglobulin. This it becomes possible to follow the development of metastases, the effectiveness of therapy applied as well as the history of the disease. The authors studied the change of thyroglobulin level in 153 patients with highly differentiated thyroid cancer. In 29 of 32 metastatic patients a pathologically elevated (70-100 ng/ml) thyroglobulin level was observed. This proves the 91% specificity of the method in verified metastatic tumours. Compared to the total body scintigraphy 3 false-negative and 6 false-positive cases were found. The authors establish that, irrespective of the site of metastasis, the thyroglobulin level is higher in the follicular than in the papillary subtype. It is concluded that the measurement of the serum thyroglobulin level is a suitable marker of the highly differentiated thyroid cancer since it indicates local recurrence or distant metastases by a significant increase while therapy-resultant tumour diminution is accompanied by a marked decrease.
Collapse
Affiliation(s)
- J Szántó
- Department of Chemotherapy, National Institute of Oncology, Budapest, Hungary
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Számel I, Hindy I, Vincze B, Kerpel-Fronius S, Eckhardt S. Influence of antiestrogen drugs on the sex hormone and sex hormone-binding globulin levels in breast cancer patients. Ann N Y Acad Sci 1988; 538:265-79. [PMID: 2973277 DOI: 10.1111/j.1749-6632.1988.tb48871.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- I Számel
- National Institute of Oncology, Budapest, Hungary
| | | | | | | | | |
Collapse
|
42
|
Számel I, Vincze B, Hindy I, Hermann I, Borvendég J, Eckhardt S. Hormonal changes during a prolonged tamoxifen treatment in patients with advanced breast cancer. Oncology 1986; 43:7-11. [PMID: 3079899 DOI: 10.1159/000226095] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The effect of tamoxifen (TAM) on the serum levels of sexual hormones and on the sex hormone-binding globulin (SHBG) was investigated in 30 postmenopausal patients with advanced breast cancer. To study the 'prolactin reserve capacity' of the pituitary gland, thyrotrophin-releasing hormone (TRH) and sulpiride-induced prolactin release were measured prior to TAM treatment, then in the 2nd and 8th week of the therapy. The TRH (400 micrograms i.v.)-induced prolactin secretion was significantly suppressed by TAM after an 8-week treatment, but only in responding cases. Maximal prolactin stimulation occurred at the 15th min after TRH injection, being equal to 5,600 +/- 800 mlU/l in cancer patients, and decreasing to 2,400 +/- 150 mlU/l after 8 weeks. TAM did not suppress the sulpiride-inducable prolactin release either in responders or in nonresponders.
Collapse
|
43
|
Számel I, Vincze B, Svastits E, Tóth J, Ringwald G, Kerpel-Fronius S, Eckhardt S. [Significance of estradiol-progesterone levels in breast tissue in the management of breast cancer]. Orv Hetil 1983; 124:495-9. [PMID: 6844011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
44
|
Szántó J, Vincze B, Revitzky AL. [Screening of families of patients with medullary cancer of the thyroid]. Orv Hetil 1982; 123:1737-40. [PMID: 7122102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|